RPRX Royalty Pharmadata gap · 72% coveragelimited data
Health Care · Pharmaceutical Preparations · close $60.96 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Royalty Pharma (RPRX) has a ThetaGrade House Rating of 53/100 (grade C), ranking #71 of 150 in Health Care. Its strongest pillars are profitability (100) and growth (47); its weakest is balance sheet (28). Data gap: 5 factors without usable data, so 72% of the method weight is covered. TTM revenue growth is 10.0% and operating margin 59.6%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, 4Q gross-margin change, FCF margin, FCF yield. Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 72% of the full method weight is backed by data.
- Capex: not tagged for FY ending 2025-12-31 under standard XBRL tags - FCF data gap
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→38.5%) · 47| Revenue growth YoY (TTM) (15.4%) | 10.0% | 50 |
| EPS growth YoY (TTM) (15.4%) | -18.3% | 27 |
| Revenue acceleration (7.7%) | 5.5% | 83 |
Profitability
weight 18.5% (→23.1%) · 100| Operating margin (23.1%) | 59.6% | 100 |
| 4Q gross-margin change (0.0%)data gap | — | — |
Balance sheet
weight 18.5% (→23.1%) · 28| Net debt / EBITDA (12.3%) | 5.38× | 8 |
| Current ratio (6.2%) | 2.80 | 53 |
| Interest coverage (4.6%) | 4.91× | 49 |
Cash flow
weight 12.33% · no data · —| FCF margin (0.0%)data gap | — | — |
| FCF yield (0.0%)data gap | — | — |
Valuation
weight 12.33% (→15.4%) · 34| P/E (inverted) (7.7%) | 32.60× | 48 |
| EV/Sales (inverted) (7.7%) | 13.91× | 19 |
Technicals (EOD)
| RSI(14) | 63.2 |
| EMA 9 / 21 | 58.52 / 58.32 · crossed up 1d ago |
| 200-day SMA | 52.02 |
| Volume vs 20d avg | 1.88× |
| 20-day return | 3.4% |
Exit-rule monitor
- EXITRating break: House Rating below 60
- EXITBalance-sheet stress: net debt/EBITDA above 4×
Data source per metric (SEC XBRL tag or derivation): Revenue: Revenues · Operating income: OperatingIncomeLoss · Interest expense: InterestExpenseNonoperating · D&A: Depreciation · EPS: EarningsPerShareDiluted · Market cap: SEC shares (us-gaap weighted basic shares, latest quarter (proxy)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like RPRX's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is RPRX's House Rating?
- RPRX scores 53 out of 100 (grade C) as of 2026-10-16, ranking #71 of 150 Health Care stocks we cover.
- What do analysts say about RPRX?
- We do not have enough analyst-sentiment data to score this stock.
- When does RPRX report earnings next?
- RPRX's next earnings report is estimated for about 2026-11-04 (window 2026-11-01 to 2026-11-07), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
- Is RPRX a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology